Redrobe J P, Bourin M
GIS Médicament, JE 2027 Neurobiologie de l'anxieté, Faculté de Médicine, Nantes, France.
Eur Neuropsychopharmacol. 1998 Aug;8(3):169-73. doi: 10.1016/s0924-977x(97)00073-4.
The present study was undertaken to identify the receptor subtypes involved in clonidine's ability to enhance the effects of antidepressant drugs in the mouse forced swimming test. Clonidine (0.06 mg/kg, i.p.) significantly enhanced the antidepressant-like effects of subactive doses of the 5-HT1A receptor agonist, 8-OH-DPAT (1 mg/kg, i.p.; P<0.01); the 5-HT1A receptor antagonist, NAN 190 (0.5 mg/kg, i.p.; P<0.01); the 5-HT1A/1B autoreceptor antagonist, (+/-) pindolol (32 mg/kg, i.p.; P<0.01); the 5-HT2A/2C receptor antagonist, ritanserin (4 mg/kg, i.p.; P<0.01). Pretreatment with clonidine failed to increase mobility when administered in combination with the 5-HT1B receptor agonist, RU 24969 (1 mg/kg, i.p.) or the 5-HT2A receptor antagonist, ketanserin (8 mg/kg, i.p.). In conclusion, clonidine-induced anti-immobility effects are more likely mediated by 5-HT1A and 5-HT2C receptors, as well as alpha-2-adrenergic autoreceptors situated on noradrenergic neurones. The results of the present study also demonstrate that serotonergic receptor function can influence alpha-2-adrenoreceptor mediated responses in the mouse forced swimming test.
本研究旨在确定可乐定在小鼠强迫游泳试验中增强抗抑郁药作用所涉及的受体亚型。可乐定(0.06毫克/千克,腹腔注射)显著增强了5-HT1A受体激动剂8-OH-DPAT(1毫克/千克,腹腔注射;P<0.01)、5-HT1A受体拮抗剂NAN 190(0.5毫克/千克,腹腔注射;P<0.01)、5-HT1A/1B自身受体拮抗剂(±)吲哚洛尔(32毫克/千克,腹腔注射;P<0.01)、5-HT2A/2C受体拮抗剂利坦色林(4毫克/千克,腹腔注射;P<0.01)亚有效剂量的抗抑郁样作用。可乐定预处理与5-HT1B受体激动剂RU 24969(1毫克/千克,腹腔注射)或5-HT2A受体拮抗剂酮色林(8毫克/千克,腹腔注射)联合给药时,未能增加活动能力。总之,可乐定诱导的抗不动作用更可能由5-HT1A和5-HT2C受体以及去甲肾上腺素能神经元上的α-2-肾上腺素能自身受体介导。本研究结果还表明,在小鼠强迫游泳试验中,5-羟色胺能受体功能可影响α-2-肾上腺素能受体介导的反应。